Nektar Therapeutics | NKTR - 资产



金融业
股票价格
USD
资产
USD 280.41M
现金及等价物
USD 15.12M
销售成本
USD 4.44M
流动资产
USD 266.27M
流动负债
USD 53.54M
债务
USD 0
股息收益率
0
EBIT
USD -19.09M
EBITDA
USD -31.81M
员工
137
EPS每股收益
USD -1.35
股本和储备
USD 89.83M
销售毛利
USD 21.81M
债务利息支出
USD 9.77M
利息收入
USD -0.18
贷款资金
USD 63.16M
市值
USD 12.23B
净收入
USD -36.08M
营业费用
USD 40.9M
营业利润
USD -19.09M
普通股股本
USD 20.38M
税前利润
USD -34.7M
销售收入
USD 21.81M
销售和管理费用
USD 10.17M
股票
USD 14.46M
贸易债权人
USD 10.77M
应收帐款人
USD 1.78M


资产 更改 日
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
ALKERMES USD 4.26B 1.77B 2026-03
Alterity Therapeutics Limited AUD 37.98M 15.78M 2025-12
Amgen USD 92.5B 1.92B 2026-03
Baxter International USD 19.85B 209M 2026-03
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
Biogen USD 29.48B 43.6M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Cara Therapeutics USD 32.07M 6.95M 2025-12
Cipla INR 424.96B 23.32B 2026-03
Dr.Reddys Laboratories INR 581.23B 18.34B 2026-03
Eisai JPY 1.45T 37.11B 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Esperion Therapeutics USD 462.53M 3.36M 2026-03
Exelixis USD 2.59B 250.83M 2026-03
Gilead Sciences USD 56.28B 2.74B 2026-03
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Grifols EUR 23.15B 142.7M 2025-12
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Incyte USD 7.34B 381.14M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Ironwood Pharmaceuticals USD 434.57M 37.66M 2026-03
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
MacroGenics USD 217.87M 38.97M 2026-03
Merck USD 128.68B 8.18B 2026-03
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Novartis USD 118.53B 7.58B 2026-03
Pfizer USD 207.62B 542M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
Takeda JPY 15.45T 44.34B 2026-03
Teva Pharmaceutical Industries USD 40.04B 708M 2026-03
Xencor USD 736.85M 138.65M 2026-03